Insiders Advisor
  • Stocks
  • World News
  • Business
  • Politics
  • Stocks
  • World News
  • Business
  • Politics

Insiders Advisor

Politics

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

by November 26, 2024
November 26, 2024
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS
previous post
Trump, Congress looking to put suffocating sanctions on ‘kangaroo’ ICC over Netanyahu arrest warrant
next post
Stop funding the woke and the stupid

Related Posts

Trump, eyeing 3rd term, keeps attacking elite institutions...

April 1, 2025

Iran accuses Israel of blowing up natural gas...

February 22, 2024

Dem senator accuses top Trump official of being...

June 26, 2025

David Marcus: Meet the RFK Jr voters who...

August 22, 2024

Acting head of Social Security quits after clash...

February 18, 2025

America First Legal sues FEC to force action...

March 3, 2024

Kamala Harris to accept presidential nomination on final...

August 22, 2024

Trump administration cutting 90% of USAID foreign aid...

February 27, 2025

Obama-appointed judge who became Trump rival during election...

February 18, 2025

Potential Trump running mate Tom Cotton took hard...

May 28, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Latest News

    • Israel releases conversations with Gaza residents amid criticisms of aid delivery system

      July 1, 2025
    • Iran, following Trump strikes, says ‘the doors of diplomacy will never slam shut’

      July 1, 2025
    • Elon Musk’s attacks on Trump’s ‘big, beautiful bill’ have ‘no basis,’ says No 2 House Republican

      July 1, 2025
    • Trump says DOGE ‘monster’ may have to ‘eat Elon’ as Musk vows primary ads for lawmakers who cross him on BBB

      July 1, 2025
    • Senate parliamentarian OKs ban on Planned Parenthood federal funding in Trump megabill

      July 1, 2025
    • 4 Senate amendments to Trump megabill that failed — and 1 that passed

      July 1, 2025

    Categories

    • Business (1,288)
    • Politics (6,227)
    • Stocks (904)
    • World News (460)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: insidersadvisor.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 insidersadvisor.com | All Rights Reserved